Search

Displaying results 3131 - 3140 of 10000 in total
  1. Drug

    Lumiliximab

    go.drugbank.com/drugs/DB06162
    Investigational

    Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007. Results published from the CLL clinical trial failed to meet primary endpoints. … Lumiliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.

    Synonyms: IMMUNOGLOBULIN G1, ANTI-(HUMAN IMMUNOGLOBULIN E RECEPTOR TYPE II) (HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .KAPPA.-CHAIN, DIMER, IMMUNOGLOBULIN G1, ANTI-(HUMAN IMMUNOGLOBULIN E RECEPTOR TYPE II) (HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .GAMMA.1-CHAIN), DISULPHIDE WITH HUMAN-MACACA IRUS MONOCLONAL IDEC-152 .KAPPA.-CHAIN, DIMER
  2. Drug

    Burosumab

    go.drugbank.com/drugs/DB14012
    ApprovedInvestigational

    Burosumab (KRN23) is an entirely human monoclonal IgG1 antibody that binds excess fibroblast growth factor 23 (FGF23) and has been successfully tested in clinical trials in children with X-linked hypophosphatemic … Food and Drug Administration approved Crysvita (burosumab) in April 2018.

  3. Drug

    Daclizumab

    go.drugbank.com/drugs/DB00111
    ApprovedInvestigationalWithdrawn

    in de novo allogeneic renal transplantation and used concomitantly with an immunosuppressive regimen like cyclosporine and corticosteroids in patients who are not hight immunized, for commercial reasons … The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody.

    Products: Zinbryta Pen
  4. Drug

    Arotinolol

    go.drugbank.com/drugs/DB09204
    Investigational

    Arotinolol is an alpha- and beta-receptor blocker developed in Japan. It is a thiopropanolamine with a tertiary butyl moiety. It has been studied for its potential to be an antihypertensive therapy.

  5. Drug

    Zidebactam

    go.drugbank.com/drugs/DB13090
    Approved

    Zidebactam is a diazabicyclooctane that acts both as a beta-lactamase inhibitor and as an antibacterial in its own right, selectively binding penicillin-binding protein 2. … [L63350] It is available only in fixed combination with [cefepime], which binds PBP3 and PBP1a/b.

  6. Drug

    Esterified estrogens

    go.drugbank.com/drugs/DB09381
    Approved

    Esterified estrogens are a man-made mixture of estrogens that are used to treat symptoms of menopause such as hot flashes, vaginal dryness, vaginal burning or irritation, or other hormonal changes in the

  7. Drug

    Zoliflodacin

    go.drugbank.com/drugs/DB12817
    ApprovedInvestigational

    FDA in December 2025, following Fast Track, Qualified Infectious Disease Product, and Priority Review designations.[L54743,L54803] … [A275268] Zoliflodacin is a first-in-class spiropyrimidinetrione antibiotic designed to address this need by inhibiting bacterial type II topoisomerases (DNA gyrase and topoisomerase IV), thereby blocking

  8. Drug

    Enzalutamide

    go.drugbank.com/drugs/DB08899
    ApprovedInvestigational

    [L40639] It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012. … [A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007.

  9. Drug

    Nafcillin

    go.drugbank.com/drugs/DB00607
    ApprovedInvestigational

    It may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections [A20360].

  10. Drug

    Favipiravir

    go.drugbank.com/drugs/DB12466
    ApprovedInvestigational

    Discovered by Toyama Chemical Co., Ltd. in Japan, favipiravir is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza. … [A191688,A191772,A191775] Not only does favipiravir inhibit replication of influenza A and B, but the drug has shown promise in the treatment of avian influenza, and may be an alternative option for